# Olivier Briand

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 103 papers | 17,327 citations | 30070 54 h-index | 33894 99 g-index |
| 104 all docs | 104 docs citations | 104 times ranked | 17403 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312. | | 5 |
| 2 | Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients, 2022, 14, 2707. | 4.1 | 8 |
| 3 | Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E772-E783. | 3.5 | 8 |
| 4 | PPAR control of metabolism and cardiovascular functions. Nature Reviews Cardiology, 2021, 18, 809-823. | 13.7 | 299 |
| 5 | Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2021, 123, 154844. | 3.4 | 20 |
| 6 | Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System. Frontiers in Molecular Neuroscience, 2021, 14, 808603. | 2.9 | 9 |
| 7 | Intestinal miRNAs regulated in response to dietary lipids. Scientific Reports, 2020, 10, 18921. | 3.3 | 11 |
| 8 | Intestinal Lipid Metabolism Genes Regulated by miRNAs. Frontiers in Genetics, 2020, 11, 707. | 2.3 | 12 |
| 9 | The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids. Scientific Reports, 2020, 10, 174. | 3.3 | 45 |
| 10 | FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements. Journal of Lipid Research, 2019, 60, 1547-1561. | 4.2 | 19 |
| 11 | Postprandial Circulating miRNAs in Response to a Dietary Fat Challenge. Nutrients, 2019, 11, 1326. | 4.1 | 29 |
| 12 | Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. Diabetes, 2018, 67, 1310-1321. | 0.6 | 64 |
| 13 | Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut, 2018, 67, 271-283. | 12.1 | 150 |
| 14 | Molecular Actions of PPARÎ± in Lipid Metabolism and Inflammation. Endocrine Reviews, 2018, 39, 760-802. | 20.1 | 420 |
| 15 | The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis. Journal of Hepatology, 2018, 69, 1099-1109. | 3.7 | 40 |
| 16 | Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity. JCI Insight, 2018, 3, . | 5.0 | 4 |
| 17 | Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2017, 152, 1679-1694.e3. | 1.3 | 630 |
| 18 | The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPARÎ³. Scientific Reports, 2017, 7, 14087. | 3.3 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3783-3794. | 3.6 | 78 |
| 20 | Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia. Acta Diabetologica, 2017, 54, 191-199. | 2.5 | 10 |
| 21 | Intestinal bile acid receptors are key regulators of glucose homeostasis. Proceedings of the Nutrition Society, 2017, 76, 192-202. | 1.0 | 27 |
| 22 | PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nature Reviews Endocrinology, 2017, 13, 36-49. | 9.6 | 509 |
| 23 | Distinct but complementary contributions of PPAR isotypes to energy homeostasis. Journal of Clinical Investigation, 2017, 127, 1202-1214. | 8.2 | 270 |
| 24 | Metabolic effects of bile acid sequestration. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 138-144. | 2.3 | 9 |
| 25 | Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. Gastroenterology, 2016, 150, 650-658. | 1.3 | 41 |
| 26 | The novel selective PPARÎ± modulator (SPPARMÎ±) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis, 2016, 249, 200-208. | 0.8 | 107 |
| 27 | Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nature Communications, 2015, 6, 7629. | 12.8 | 274 |
| 28 | Nuclear bile acid signaling through the farnesoid X receptor. Cellular and Molecular Life Sciences, 2015, 72, 1631-1650. | 5.4 | 92 |
| 29 | <scp>PPAR</scp>Î± is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke. Fundamental and Clinical Pharmacology, 2014, 28, 294-302. | 1.9 | 12 |
| 30 | Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology, 2014, 59, 2022-2033. | 7.3 | 55 |
| 31 | A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation. Nucleic Acids Research, 2014, 42, 10943-10959. | 14.5 | 71 |
| 32 | Failing FXR expression in the liver links aging to hepatic steatosis. Journal of Hepatology, 2014, 60, 689-690. | 3.7 | 15 |
| 33 | Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends in Endocrinology and Metabolism, 2014, 25, 235-244. | 7.1 | 43 |
| 34 | O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing. Frontiers in Endocrinology, 2014, 5, 230. | 3.5 | 28 |
| 35 | The Hepatic Orosomucoid/Î±1-Acid Glycoprotein Gene Cluster Is Regulated by the Nuclear Bile Acid Receptor FXR. Endocrinology, 2013, 154, 3690-3701. | 2.8 | 24 |
| 36 | Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2013, 58, 1941-1952. | 7.3 | 355 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Palmitate increases <i>Nur77</i> expression by modulating ZBP89 and Sp1 binding to the <i>Nur77</i> proximal promoter in pancreatic Î²â€cells. FEBS Letters, 2013, 587, 3883-3890. | 2.8 | 13 |
| 38 | Activation of intestinal peroxisome proliferator-activated receptor-Â increases high-density lipoprotein production. European Heart Journal, 2013, 34, 2566-2574. | 2.2 | 44 |
| 39 | Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes. Molecular and Cellular Biology, 2013, 33, 2202-2211. | 2.3 | 110 |
| 40 | Soaping Up Type 2 Diabetes With Bile Acids?. Diabetes, 2013, 62, 3987-3989. | 0.6 | 11 |
| 41 | The Elongation Complex Components BRD4 and MLLT3/AF9 Are Transcriptional Coactivators of Nuclear Retinoid Receptors. PLoS ONE, 2013, 8, e64880. | 2.5 | 14 |
| 42 | PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1063-E1069. | 3.5 | 76 |
| 43 | Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. Journal of Lipid Research, 2012, 53, 1723-1737. | 4.2 | 241 |
| 44 | The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism. Archives of Physiology and Biochemistry, 2012, 118, 102-111. | 2.1 | 46 |
| 45 | The Nuclear Orphan Receptor Nur77 Is a Lipotoxicity Sensor Regulating Glucose-Induced Insulin Secretion in Pancreatic Î²-Cells. Molecular Endocrinology, 2012, 26, 399-413. | 3.7 | 38 |
| 46 | PPARÎ²/Î´ Activation Induces Enteroendocrine L Cell GLP-1 Production. Gastroenterology, 2011, 140, 1564-1574. | 1.3 | 55 |
| 47 | Effects of the New Dual PPARÎ±/Î´ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism. Diabetes Care, 2011, 34, 2008-2014. | 8.6 | 155 |
| 48 | Control of nuclear receptor activities in metabolism by postâ€translational modifications. FEBS Letters, 2011, 585, 1640-1650. | 2.8 | 53 |
| 49 | Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes. Current Diabetes Reports, 2011, 11, 160-166. | 4.2 | 201 |
| 50 | Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity. Diabetes, 2011, 60, 1861-1871. | 0.6 | 261 |
| 51 | Peroxisome Proliferatorâ€“Activated Receptor-Î± Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1573-1579. | 2.4 | 66 |
| 52 | Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 513-519. | 2.4 | 129 |
| 53 | The nuclear receptor FXR is expressed in pancreatic Î²â€cells and protects human islets from lipotoxicity. FEBS Letters, 2010, 584, 2845-2851. | 2.8 | 80 |
| 54 | Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Laboratory Investigation, 2010, 90, 1457-1467. | 3.7 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism, 2010, 12, 384-392. | 4.4 | 124 |
| 56 | Proteasomal degradation of retinoid X receptor Î± reprograms transcriptional activity of PPARÎ³ in obese mice and humans. Journal of Clinical Investigation, 2010, 120, 1454-1468. | 8.2 | 56 |
| 57 | Bile Acid Sequestrants: Glucose-Lowering Mechanisms. Metabolic Syndrome and Related Disorders, 2010, 8, S-3-S-8. | 1.3 | 23 |
| 58 | The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-Î³ and Interfering with the Wnt/Î²-Catenin Pathways. Journal of Biological Chemistry, 2010, 285, 36759-36767. | 3.4 | 79 |
| 59 | Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiological Reviews, 2009, 89, 147-191. | 28.8 | 1,309 |
| 60 | LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. Journal of Clinical Investigation, 2009, 119, 3830-3838. | 8.2 | 47 |
| 61 | Cross-talk Between Statins and PPARÎ± in Cardiovascular Diseases: Clinical Evidence and Basic Mechanisms. Trends in Cardiovascular Medicine, 2008, 18, 73-78. | 4.9 | 51 |
| 62 | Regulation of Macrophage Functions by PPAR-Î±, PPAR-Î³, and LXRs in Mice and Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1050-1059. | 2.4 | 262 |
| 63 | The PPARÎ±/p16 <sup>INK4a</sup> Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycleâ€"Dependent Telomerase Activation. Circulation Research, 2008, 103, 1155-1163. | 4.5 | 61 |
| 64 | Intestine-Specific Regulation of PPARÎ± Gene Transcription by Liver X Receptors. Endocrinology, 2008, 149, 5128-5135. | 2.8 | 29 |
| 65 | Phosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity. Molecular Endocrinology, 2008, 22, 2433-2447. | 3.7 | 66 |
| 66 | Measuring biomarkers to assess the therapeutic effects of PPAR agonists?. Pharmacogenomics, 2007, 8, 1567-1580. | 1.3 | 4 |
| 67 | Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins. Circulation Research, 2007, 100, 1394-1395. | 4.5 | 33 |
| 68 | FXRâ€deficiency confers increased susceptibility to torpor. FEBS Letters, 2007, 581, 5191-5198. | 2.8 | 30 |
| 69 | Bile???Acid???Sequestrants???and???the???Treatment of Type??2??Diabetes??Mellitus. Drugs, 2007, 67, 1383-1392. | 10.9 | 149 |
| 70 | Derivatives of Iressa, a Specific Epidermal Growth Factor Receptor Inhibitor, are Powerful Apoptosis Inducers in PC3 Prostatic Cancer Cells. ChemMedChem, 2007, 2, 318-332. | 3.2 | 13 |
| 71 | Th-W60:3 Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the PKC signalling pathway. Atherosclerosis Supplements, 2006, 7, 487. | 1.2 | 1 |
| 72 | Niemannâ€"Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochemical and Biophysical Research Communications, 2006, 340, 1259-1263. | 2.1 | 156 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. Journal of Hepatology, 2006, 44, 732-741. | 3.7 | 213 |
| 74 | Sorting out the roles of PPARÂ in energy metabolism and vascular homeostasis. Journal of Clinical Investigation, 2006, 116, 571-580. | 8.2 | 779 |
| 75 | Peroxisome Proliferator-Activated Receptor Â Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets. Diabetes, 2006, 55, 1605-1613. | 0.6 | 100 |
| 76 | The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. Journal of Biological Chemistry, 2006, 281, 11039-11049. | 3.4 | 463 |
| 77 | Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferatorâ€"Activated Receptor-Î± via Inhibition of the Protein Kinase C Signaling Pathway. Circulation Research, 2006, 98, 361-369. | 4.5 | 157 |
| 78 | Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Journal of Clinical Investigation, 2006, 116, 1052-1062. | 8.2 | 447 |
| 79 | The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition. Journal of Biological Chemistry, 2005, 280, 29971-29979. | 3.4 | 186 |
| 80 | PPARÎ±, but not PPARÎ³, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1897-1902. | 2.4 | 70 |
| 81 | Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie, 2005, 87, 93-98. | 2.6 | 32 |
| 82 | Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Letters, 2005, 579, 4076-4080. | 2.8 | 72 |
| 83 | Peroxisome Proliferator-Activated Receptors and Atherogenesis. Circulation Research, 2004, 94, 1168-1178. | 4.5 | 471 |
| 84 | The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor Î±. Molecular Endocrinology, 2004, 18, 1906-1918. | 3.7 | 97 |
| 85 | Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-Î±-dependent. Journal of Biological Chemistry, 2004, 279, 45512-45518. | 3.4 | 84 |
| 86 | Glucose Regulates the Expression of the Farnesoid X Receptor in Liver. Diabetes, 2004, 53, 890-898. | 0.6 | 226 |
| 87 | Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1684, 8-17. | 2.4 | 17 |
| 88 | Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1683, 69-77. | 2.4 | 8 |
| 89 | SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 42-50. | 2.4 | 25 |
| 90 | Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1583, 99-107. | 2.4 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | PPAR-Î± and PPAR-Î³ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine, 2001, 7, 53-58. | 30.7 | 1,075 |
| 92 | Statin-induced inhibition of the Rho-signaling pathway activates PPARÎ± and induces HDL apoA-I. Journal of Clinical Investigation, 2001, 107, 1423-1432. | 8.2 | 381 |
| 93 | Oxidized phospholipids activate PPARÎ± in a phospholipase A2-dependent manner. FEBS Letters, 2000, 471, 34-38. | 2.8 | 179 |
| 94 | Apolipoprotein AII Enrichment of HDL Enhances Their Affinity for Class B Type I Scavenger Receptor but Inhibits Specific Cholesteryl Ester Uptake. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1074-1081. | 2.4 | 44 |
| 95 | Peroxisome Proliferator-Activated Receptor Activators Inhibit Thrombin-Induced Endothelin-1 Production in Human Vascular Endothelial Cells by Inhibiting the Activator Protein-1 Signaling Pathway. Circulation Research, 1999, 85, 394-402. | 4.5 | 489 |
| 96 | Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells. FEBS Journal, 1999, 261, 481-491. | 0.2 | 56 |
| 97 | Peroxisome Proliferator-activated Receptor Î± Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-Îº B and AP-1. Journal of Biological Chemistry, 1999, 274, 32048-32054. | 3.4 | 982 |
| 98 | Apolipoprotein AII is a better ligand than apolipoprotein AI for the human HDL receptor SR-BI but alters specific cholesteryl ester uptake in human adrenal cell line. Atherosclerosis, 1999, 144, 81. | 0.8 | 0 |
| 99 | Localisation of SR-BI in caveolae is not required for cholesteryl esters selective uptake in NCI H295R adrenal cell line. Atherosclerosis, 1999, 144, 110-111. | 0.8 | 0 |
| 100 | Activation of human aortic smooth-muscle cells is inhibited by PPARÎ± but not by PPARÎ³ activators. Nature, 1998, 393, 790-793. | 27.8 | 1,104 |
| 101 | Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation, 1998, 98, 2088-2093. | 1.6 | 1,540 |
| 102 | High-density-lipoprotein subfraction 3 interaction with glycosylphosphatidylinositol-anchored proteins. Biochemical Journal, 1997, 328, 415-423. | 3.7 | 19 |
| 103 | 4.P.348 Caveolae and glycosyl phosphatidylinositol-anchored proteins: A specific binding membrane domain for high density lipoproteins. Atherosclerosis, 1997, 134, 369. | 0.8 | 1 |